Implanon Related Published Studies
Well-designed clinical trials related to Implanon (Etonogestrel Subcutaneous)
Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. [2009.12]
The efficacy of Implanon for the treatment of chronic pelvic pain associated with pelvic congestion: 1-year randomized controlled pilot study. [2009.09]
A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. [2009.08]
Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study. [2009.01]
7alpha-methyl-19-nortestosterone (MENT) vs testosterone in combination with etonogestrel implants for spermatogenic suppression in healthy men. [2007.09]
Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive. [2006.01]
A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. [2006.01]
A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive. [2006.01]
Effect on insulin sensitivity of Implanon vs. GnRH agonist in women with endometriosis. [2005.12]
A multicenter phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception. [2005.04]
Effect of etonogestrel subdermal contraceptive implant (Implanon) on liver function tests -- a randomized comparative study with Norplant implants. [2004.11]
Effect of Implanon and Norplant subdermal contraceptive implants on serum lipids--a randomized comparative study. [2003.09]
[A randomized study comparing the efficacy and bleeding pattern of Implanon and Norplant hormonal contraceptive implant] [2003.07]
Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. [2002.08]
Implanon contraceptive implants: effects on carbohydrate metabolism. [2001.03]
Effect of Implanon use on selected parameters of thyroid and adrenal function. [2000.11]
Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. [2000.09]
The effects of Implanon on lipid metabolism in comparison with Norplant. [1999.11]
Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette and Liseta. [1999.10]
A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. [1999.07]
Twenty-four month comparison of apolipoproteins A-1, A-II and B in contraceptive implant users (Norplant and Implanon) in Birmingham, United Kingdom. [1998.10]
Effects on the hemostatic system and liver function in relation to Implanon and Norplant. A prospective randomized clinical trial. [1998.08]
Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. [1998.04]
Well-designed clinical trials possibly related to Implanon (Etonogestrel Subcutaneous)
Budesonide quantification by HPLC coupled to atmospheric pressure photoionization (APPI) tandem mass spectrometry. Application to a comparative systemic bioavailability of two budesonide formulations in healthy volunteers. [2011.02.01]
Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study. [2010.03]
[Combined hormonal contraception in cycles artificially extended]. [2010.01]
Male hormonal contraception: a double-blind, placebo-controlled study. [2008.07]
Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. [2006.09]
Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. [2006.09]
A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants. [2006.02]
Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive. [2005.11]
Extended regimens of the contraceptive vaginal ring: a randomized trial. [2005.09]
The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. [2005.07]
Effects of two types of hormonal contraception--oral versus intravaginal--on the sexual life of women and their partners. [2005.04]
Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials. [2005]
The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage. [2004.03]
The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. [2004.02]
The combined contraceptive ring NuvaRing and spermicide co-medication. [2003.04]
Complete and robust ovulation inhibition with NuvaRing. [2002.12]
Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. [2001.05]
The effect of low-dose 3-keto-desogestrel added to a copper-releasing intrauterine contraceptive device on menstrual blood loss: a double-blind, dose-finding, placebo-controlled study. [2000.03]
Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. [1999.01]
A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK. [1998.11]
Prodrug versus drug effects of 150 micrograms desogestrel or 3-keto-desogestrel in combination with 30 micrograms ethinylestradiol on hormonal parameters: relevance of the peak serum level of 3-keto-desogestrel. [1995]
Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene. [1994.10]
Pharmacokinetics and protein binding of 3-ketodesogestrel and gestodene in the serum of women during 6 cycles of treatment with two low dose oral contraceptives. [1993.12]
Pharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive. [1992.09]
Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings. [1990.10]
The in vivo release characteristics of a multi-compartment vaginal ring releasing 3-keto-desogestrel. [1989.11]
Pharmacodynamics of a contraceptive vaginal ring releasing 3-keto-desogestrel. [1989.06]
Other research related to Implanon (Etonogestrel Subcutaneous)
A randomized study of the effect of mifepristone alone or in conjunction with ethinyl estradiol on ovarian function in women using the etonogestrel-releasing subdermal implant, Implanon(R). [2011.12]
Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism. [2011.08]
Implanon(R) failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies. [2011.07]
Ectopic pregnancy with Implanon(R) as a method of contraception in a woman with a previous ectopic pregnancy - case report. [2011.06]
Bleeding related to etonogestrel subdermal implant in a US population. [2011.05]
Etonogestrel implant in adolescents: evaluation of clinical aspects. [2011.04]
The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. [2011.03]
[Pregnancy with Implanon: a report on three cases]. [2011.02]
Implanon use lowers plasma concentrations of high-molecular-weight adiponectin. [2011.01]
Menstrual bleeding patterns in adolescents using etonogestrel (ENG) implant. [2011]
A randomized study of the effect of mifepristone alone or in conjunction with
ethinyl estradiol on ovarian function in women using the etonogestrel-releasing
subdermal implant, Implanon®. [2011]
Safety, efficacy and acceptability of implanon a single rod implantable contraceptive (etonogestrel) in University of Benin Teaching Hospital. [2010.09]
Etonogestrel implant in postpartum adolescents: bleeding pattern, efficacy and discontinuation rate. [2010.09]
Clinician satisfaction and insertion characteristics of a new applicator to insert radiopaque Implanon: an open-label, noncontrolled, multicenter trial. [2010.09]
Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels. [2010.06]
Bone mineral density in women using the subdermal contraceptive implant Implanon for at least 2 years. [2010.06]
Implanon as a contraceptive choice for teenage mothers: a comparison of contraceptive choices, acceptability and repeat pregnancy. [2010.05]
Cerebral venous sinus thrombosis in a woman using the etonogestrel-ethinyl estradiol vaginal contraceptive ring: a case report. [2010.03]
Levonorgestrel, not etonogestrel, provides contraception in free-ranging koalas. [2010]
Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland, Australia. [2009.12]
Implanon users are less likely to be satisfied with their contraception after 6 months than IUD users. [2009.11]
Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain. [2009.11]
Ultrasound appearances of Implanon implanted contraceptive devices. [2009.09]
Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. [2009.05]
Actual cost of providing long-acting reversible contraception: a study of Implanon cost. [2009.04]
The cost-effectiveness of a long-acting reversible contraceptive (Implanon) relative to oral contraception in a community setting. [2009.04]
[Sociodemographic characteristics of users of the contraceptive implant releasing etonogestrel] [2009.03]
Implanon: a review of the literature with recommendations for clinical management. [2009.03]
The efficacy of Implanon for the treatment of chronic pelvic pain associated with pelvic congestion: 1-year randomized controlled pilot study. [2009.02.04]
Etonogestrel implant as a contraceptive choice; patient acceptability and adverse effect profile in a general practice setting. [2009.01]
Implanon sub-dermal implants: a 10-month review of acceptability in Jos, North-Central Nigeria. [2008.12]
Etonogestrel implant in women with diabetes mellitus. [2008.12]
Assessment of Implanon insertion and removal. [2008.11]
Ultrasound-guided removal of Implanon devices. [2008.11]
Effects of the progestagen-only contraceptive implant Implanon on transforming growth factor beta1 and endothelin-1. [2008.10]
Tolerability and clinical safety of Implanon. [2008.06]
The effects of Implanon on menstrual bleeding patterns. [2008.06]
The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. [2008.06]
Implanon: a new contraceptive implant. [2008.05]
Effects of the progestagen-only contraceptive implant Implanon on cardiovascular risk factors. [2008.03]
Contraceptive efficacy and side effects of Implanon. [2007.12]
Side effects and acceptability of Implanon: a pilot study conducted in eastern Turkey. [2007.09]
The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring. [2007.08]
Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. [2007.08]
Simultaneous use of a levonorgestrel intrauterine system and an etonogestrel subdermal implant for debilitating adolescent endometriosis. [2007.06]
The effects of implanon in the symptomatic treatment of endometriosis. [2005.10]
Other possibly related research studies
The decline of laparoscopic sterilisation. [2008.02]
Progress and prospects in male hormonal contraception. [2008.06]
The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline. [2008.06]
The contraceptive implant. [2007.12]
Contraceptive vaginal ring. [2007.12]
|
